297 related articles for article (PubMed ID: 25345732)
21. Adverse childhood experiences influence the detrimental effect of bipolar disorder and schizophrenia on cortico-limbic grey matter volumes.
Poletti S; Vai B; Smeraldi E; Cavallaro R; Colombo C; Benedetti F
J Affect Disord; 2016 Jan; 189():290-7. PubMed ID: 26454335
[TBL] [Abstract][Full Text] [Related]
22. Glycogen synthase kinase-3β in patients with bipolar I disorder: results from a prospective study.
Jacoby AS; Munkholm K; Vinberg M; Joaquim HG; Talib LL; Gattaz WF; Kessing LV
Bipolar Disord; 2016 Jun; 18(4):334-41. PubMed ID: 27325150
[TBL] [Abstract][Full Text] [Related]
23. Association between GSK-3beta -50T/C polymorphism and personality and psychotic symptoms in mood disorders.
Serretti A; Benedetti F; Mandelli L; Calati R; Caneva B; Lorenzi C; Fontana V; Colombo C; Smeraldi E
Psychiatry Res; 2008 Mar; 158(2):132-40. PubMed ID: 17976739
[TBL] [Abstract][Full Text] [Related]
24. Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder.
Gildengers AG; Butters MA; Aizenstein HJ; Marron MM; Emanuel J; Anderson SJ; Weissfeld LA; Becker JT; Lopez OL; Mulsant BH; Reynolds CF
Bipolar Disord; 2015 May; 17(3):248-56. PubMed ID: 25257942
[TBL] [Abstract][Full Text] [Related]
25. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP.
Benedetti F; Serretti A; Pontiggia A; Bernasconi A; Lorenzi C; Colombo C; Smeraldi E
Neurosci Lett; 2005 Mar; 376(1):51-5. PubMed ID: 15694273
[TBL] [Abstract][Full Text] [Related]
26. GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis.
Tang H; Shen N; Jin H; Liu D; Miao X; Zhu LQ
Mol Neurobiol; 2013 Dec; 48(3):404-11. PubMed ID: 23440732
[TBL] [Abstract][Full Text] [Related]
27. Glycogen synthase kinase 3beta as a likely target for the action of lithium on circadian clocks.
Padiath QS; Paranjpe D; Jain S; Sharma VK
Chronobiol Int; 2004 Jan; 21(1):43-55. PubMed ID: 15129823
[TBL] [Abstract][Full Text] [Related]
28. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder.
Matsuo K; Walss-Bass C; Nery FG; Nicoletti MA; Hatch JP; Frey BN; Monkul ES; Zunta-Soares GB; Bowden CL; Escamilla MA; Soares JC
Neuropsychopharmacology; 2009 Jul; 34(8):1904-13. PubMed ID: 19295510
[TBL] [Abstract][Full Text] [Related]
29. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment.
Pandey GN; Ren X; Rizavi HS; Dwivedi Y
J Psychiatr Res; 2010 Feb; 44(3):143-8. PubMed ID: 19717166
[TBL] [Abstract][Full Text] [Related]
30. Lithium increases platelet serine-9 phosphorylated GSK-3β levels in drug-free bipolar disorder during depressive episodes.
de Sousa RT; Zanetti MV; Talib LL; Serpa MH; Chaim TM; Carvalho AF; Brunoni AR; Busatto GF; Gattaz WF; Machado-Vieira R
J Psychiatr Res; 2015 Mar; 62():78-83. PubMed ID: 25691093
[TBL] [Abstract][Full Text] [Related]
31. Lymphocyte Phospho-Ser-9-GSK-3β/Total GSK-3β Protein Levels Ratio Is Not Affected by Chronic Lithium or Valproate Treatment in Euthymic Patients With Bipolar Disorder.
Azab AN; Vainer E; Agam G; Bersudsky Y
J Clin Psychopharmacol; 2017 Apr; 37(2):226-230. PubMed ID: 28106616
[TBL] [Abstract][Full Text] [Related]
32. Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder.
Inkster B; Nichols TE; Saemann PG; Auer DP; Holsboer F; Muglia P; Matthews PM
Arch Gen Psychiatry; 2009 Jul; 66(7):721-8. PubMed ID: 19581563
[TBL] [Abstract][Full Text] [Related]
33. The association of glycogen synthase kinase-3beta (GSK-3β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients.
Rybakowski JK; Abramowicz M; Szczepankiewicz A; Michalak M; Hauser J; Czekalski S
Int J Bipolar Disord; 2013; 1():8. PubMed ID: 25505675
[TBL] [Abstract][Full Text] [Related]
34. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P
J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518
[TBL] [Abstract][Full Text] [Related]
35. Genetic or pharmacological superoxide-hydrogen peroxide imbalances modulate the in vitro effects of lithium on glycogen synthase kinase-3β.
Barbisan F; Azzolin VF; Monteiro GC; Teixeira CF; Mastella MH; Bueno V; Duarte MMMF; Wagner G; do Prado-Lima PAS; Ribeiro EE; da Cruz IBM
Gene; 2018 May; 655():48-55. PubMed ID: 29466765
[TBL] [Abstract][Full Text] [Related]
36. Haplotype analysis of GSK-3β gene polymorphisms in bipolar disorder lithium responders and nonresponders.
Iwahashi K; Nishizawa D; Narita S; Numajiri M; Murayama O; Yoshihara E; Onozawa Y; Nagahori K; Fukamauchi F; Ikeda K; Ishigooka J
Clin Neuropharmacol; 2014; 37(4):108-10. PubMed ID: 24992082
[TBL] [Abstract][Full Text] [Related]
37. Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice.
Kozikowski AP; Gunosewoyo H; Guo S; Gaisina IN; Walter RL; Ketcherside A; McClung CA; Mesecar AD; Caldarone B
ChemMedChem; 2011 Sep; 6(9):1593-602. PubMed ID: 21732538
[TBL] [Abstract][Full Text] [Related]
38. Gray and white matter differences in adolescents and young adults with prior suicide attempts across bipolar and major depressive disorders.
Fan S; Lippard ETC; Sankar A; Wallace A; Johnston JAY; Wang F; Pittman B; Spencer L; Oquendo MA; Blumberg HP
J Affect Disord; 2019 Feb; 245():1089-1097. PubMed ID: 30699851
[TBL] [Abstract][Full Text] [Related]
39. TRPM2, a Susceptibility Gene for Bipolar Disorder, Regulates Glycogen Synthase Kinase-3 Activity in the Brain.
Jang Y; Lee SH; Lee B; Jung S; Khalid A; Uchida K; Tominaga M; Jeon D; Oh U
J Neurosci; 2015 Aug; 35(34):11811-23. PubMed ID: 26311765
[TBL] [Abstract][Full Text] [Related]
40. Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results.
Bersudsky Y; Shaldubina A; Kozlovsky N; Woodgett JR; Agam G; Belmaker RH
Behav Pharmacol; 2008 May; 19(3):217-24. PubMed ID: 18469539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
